Evidence map›Paper›PMID 33109723›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Abnormal morphology biases hematocrit distribution in tumor vasculature and contributes to heterogeneity in tissue oxygenation.

Miguel O Bernabeu, Jakub Köry, James A Grogan, Bostjan Markelc, Albert Beardo, Mayeul d'Avezac, Romain Enjalbert, Jakob Kaeppler, Nicholas Daly, James Hetherington and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Miguel O BernabeuCentre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh EH16 4UX, United Kingdom; Miguel.Bernabeu@ed.ac.uk helen.byrne@maths.ox.ac.uk.ORCID 0000-0002-6456-3756
Jakub KöryMathematical Institute, University of Oxford, Oxford OX2 6GG, United Kingdom.ORCID 0000-0002-4476-2547
James A GroganMathematical Institute, University of Oxford, Oxford OX2 6GG, United Kingdom.
Bostjan MarkelcDepartment of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.ORCID 0000-0002-8674-702X
Albert BeardoCentre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh EH16 4UX, United Kingdom.ORCID 0000-0003-1889-1588
Mayeul d'AvezacResearch Software Development Group, Research IT Services, University College London, London WC1E 6BT, United Kingdom.
Romain EnjalbertCentre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh EH16 4UX, United Kingdom.ORCID 0000-0001-9685-5764
Jakob KaepplerDepartment of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.ORCID 0000-0001-5973-0049
Nicholas DalyCentre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh EH16 4UX, United Kingdom.
James HetheringtonThe Alan Turing Institute, London NW1 2DB, United Kingdom.
Timm KrügerSchool of Engineering, Institute for Multiscale Thermofluids, The University of Edinburgh, Edinburgh EH9 3FD, United Kingdom.ORCID 0000-0003-2934-2699
Philip K MainiMathematical Institute, University of Oxford, Oxford OX2 6GG, United Kingdom.ORCID 0000-0002-0146-9164
Joe M Pitt-FrancisDepartment of Computer Science, University of Oxford, Oxford OX1 3QD, United Kingdom.ORCID 0000-0002-5094-5403
Ruth J MuschelDepartment of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Tomás AlarcónCentre de Recerca Matemàtica, 08193 Barcelona, Spain.
Helen M ByrneMathematical Institute, University of Oxford, Oxford OX2 6GG, United Kingdom; Miguel.Bernabeu@ed.ac.uk helen.byrne@maths.ox.ac.uk.ORCID 0000-0003-1771-5910
University of Oxford · GBUniversity of Edinburgh · GBInstitució Catalana de Recerca i Estudis Avançats · ESInstitute of Oncology Ljubljana · SITuring Institute · GBUniversity College London · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M025888/1Cancer Research UK C5255/A15935Cancer Research UK C5255/A18085
6 · The paper itself

Abstract

Oxygen heterogeneity in solid tumors is recognized as a limiting factor for therapeutic efficacy. This heterogeneity arises from the abnormal vascular structure of the tumor, but the precise mechanisms linking abnormal structure and compromised oxygen transport are only partially understood. In this paper, we investigate the role that red blood cell (RBC) transport plays in establishing oxygen heterogeneity in tumor tissue. We focus on heterogeneity driven by network effects, which are challenging to observe experimentally due to the reduced fields of view typically considered. Motivated by our findings of abnormal vascular patterns linked to deviations from current RBC transport theory, we calculated average vessel lengths [Formula: see text] and diameters [Formula: see text] from tumor allografts of three cancer cell lines and observed a substantial reduction in the ratio [Formula: see text] compared to physiological conditions. Mathematical modeling reveals that small values of the ratio λ (i.e., [Formula: see text]) can bias hematocrit distribution in tumor vascular networks and drive heterogeneous oxygenation of tumor tissue. Finally, we show an increase in the value of λ in tumor vascular networks following treatment with the antiangiogenic cancer agent DC101. Based on our findings, we propose λ as an effective way of monitoring the efficacy of antiangiogenic agents and as a proxy measure of perfusion and oxygenation in tumor tissue undergoing antiangiogenic treatment.

Indexed as

Angiogenesis InhibitorsAnimalsBiomarkers, TumorBlood CirculationCell Line, TumorErythrocytesGenetic HeterogeneityHematocritMaleMiceMice, Inbred C57BLMice, TransgenicModels, BiologicalModels, TheoreticalNeoplasmsNeovascularization, PathologicAngiogenesis InhibitorsBiomarkers, TumorOxygenanti-angiogenic agentshematocrit dynamicsmathematical modellingoxygen heterogeneitytumor vasculature

Identifiers

PMID33109723
PMCPMC7668105
OpenAlexW3082181200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.